Considerations on Thrombotic Events Following Administration of the OXford-AstraZeneca COVID-19 Vaccine in Europe, 7 April 2021
Abstract
The Pan American Health Organization (PAHO) has issued this communiqué in response to the information circulating about potential risks associated with use of the COVID-19 vaccine developed by AstraZeneca and Oxford University, considering the reports of events in European countries. This communiqué offers an overview of the adverse effects following the administration of the Oxford–AstraZeneca COVID-19 vaccine notified in Europe, and of the recommendations issued by the World Health Organization, the European Medicines Agency, and other national regulatory authorities in that respect. In addition, it includes the recommendations of the Pan American Health Organization in consideration of the information and the evidence available.
Subject
Collections
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO
Related items
Showing items related by title, author, creator and subject.
-
(2022)[ABSTRACT]. There is a lack of real-world surveillance studies on reports of adverse events associated with COVID-19 vaccination, as well as comparative analyses of adverse events from vaccines with different platforms. ...
-
(2021)[ABSTRACT]. COVID-19 vaccination began in São Paulo, Brazil in January 2021, first targeting healthcare workers (HCWs) and the elderly, using the CoronaVac vaccine (Sinovac/Butantan) and subsequently the Oxford/AstraZeneca ...
-
(2022)[RESUMEN]. Objetivo. Estimar el impacto presupuestal de la vacunación contra COVID-19 en seis países de América Latina: Argentina, Brasil, Chile, Colombia, México y Perú, durante el periodo 2021-2022. Métodos. Se evaluaron ...
